- This topic is empty.
Viewing 0 reply threads
-
Posts
-
-
Overall, first-line use of Genentech’s Ocrevus for MS patients has remained stable through 2019 compared to 2018, according to Spherix Global Insights. Read more here.
What do you think of this information?
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.
